Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China.
Front Immunol. 2023 Aug 3;14:1140463. doi: 10.3389/fimmu.2023.1140463. eCollection 2023.
Immunotherapy has been emerging as a powerful strategy for cancer management. Recently, accumulating evidence has demonstrated that bacteria-based immunotherapy including naive bacteria, bacterial components, and bacterial derivatives, can modulate immune response various cellular and molecular pathways. The key mechanisms of bacterial antitumor immunity include inducing immune cells to kill tumor cells directly or reverse the immunosuppressive microenvironment. Currently, bacterial antigens synthesized as vaccine candidates by bioengineering technology are novel antitumor immunotherapy. Especially the combination therapy of bacterial vaccine with conventional therapies may further achieve enhanced therapeutic benefits against cancers. However, the clinical translation of bacteria-based immunotherapy is limited for biosafety concerns and non-uniform production standards. In this review, we aim to summarize immunotherapy strategies based on advanced bacterial therapeutics and discuss their potential for cancer management, we will also propose approaches for optimizing bacteria-based immunotherapy for facilitating clinical translation.
免疫疗法作为癌症管理的一种强有力策略正在兴起。最近，越来越多的证据表明，包括原始细菌、细菌成分和细菌衍生物在内的基于细菌的免疫疗法，可以调节免疫反应的各种细胞和分子途径。细菌抗肿瘤免疫的关键机制包括诱导免疫细胞直接杀死肿瘤细胞或逆转免疫抑制微环境。目前，通过生物技术合成的细菌抗原作为疫苗候选物是一种新型的抗肿瘤免疫疗法。特别是细菌疫苗与常规疗法的联合治疗可能会进一步提高癌症的治疗效果。然而，由于生物安全性问题和生产标准不统一，基于细菌的免疫疗法的临床转化受到限制。在这篇综述中，我们旨在总结基于先进细菌治疗的免疫疗法策略，并讨论其在癌症管理中的潜力，我们还将提出优化基于细菌的免疫疗法以促进临床转化的方法。
